Zobrazeno 1 - 10
of 675
pro vyhledávání: '"Relapsed-refractory multiple myeloma"'
Autor:
Yuhan Yan, Yixuan Tu, Qian Cheng, Jian Zhang, Erhua Wang, Zuqun Deng, Yan Yu, Liwen Wang, Rui Liu, Ling Chu, Liqing Kang, Jing Liu, Xin Li
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR T-cell) therapy has exhibited remarkable efficacy in refractory or relapsed multiple myeloma (R/R MM), but recurrence and rapid progression of disease
Externí odkaz:
https://doaj.org/article/a60950bfb0a443be87c9a362b63aaf60
Autor:
Chieh-Lin Jerry Teng, Su-Peng Yeh, Tsai-Yun Chen, Yu-Chin Hung, Yun-Chu Lin, Sin Syue Li, Ming-Chung Wang, Shang-Yi Huang
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Background/purpose The treatment landscape of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving in Taiwan. The present study aimed to assess the treatment patterns among RRMM patients in Taiwan.Methods This retrospective, chart review-b
Externí odkaz:
https://doaj.org/article/9593eb70b29941de9fe5b26697691dd5
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Venetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL2), as a targeted therapy for multiple myeloma (MM) patients. It was initially approved by the United States Food and Drug Administration for the treatment of chr
Externí odkaz:
https://doaj.org/article/9c59153d5af146aeb7865719eb56c1fe
Autor:
Wee-Joo Chng, Chandramouli Nagarajan, Shang-Yi Huang, Pankaj Malhotra, Yu-Yan Hwang, Vivian Blunk, Manmohan Singh, Lin Wang
Publikováno v:
Heliyon, Vol 10, Iss 21, Pp e39698- (2024)
Multiple myeloma (MM) accounts for almost 15 % of all neoplastic malignancies around the globe. This systematic review intends to analyse data on the treatment and management of MM in selected regions in Asia to identify and prioritize areas that nee
Externí odkaz:
https://doaj.org/article/f234975d478044bc8c3dd95cf441fbb4
Autor:
Paula Rodriguez-Otero, Thomas Martin
Publikováno v:
Hemato, Vol 5, Iss 2, Pp 171-179 (2024)
The treatment of relapsed and refractory multiple myeloma has improved substantially in the last 5–10 years based on the development and use of several novel classes of drugs and drug combinations. These advances have led to improvements in progres
Externí odkaz:
https://doaj.org/article/f1fcc3e73eef4e409a17047281c1673a
Autor:
Meletios Dimopoulos, Pieter Sonneveld, Salomon Manier, Annette Lam, Tito Roccia, Jordan M. Schecter, Patricia Cost, Lida Pacaud, Abbey Poirier, Gabriel Tremblay, Tommy Lan, Satish Valluri, Shaji Kumar
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Objectives The goal of the research was to assess the quantitative relationship between median progression-free survival (PFS) and median overall survival (OS) specifically among patients with relapsed/refractory multiple myeloma (RRMM) base
Externí odkaz:
https://doaj.org/article/0585a86fa1414c2e9c7c39d6be67cf00
Autor:
Niels vanNieuwenhuijzen, Marta Cuenca, Leonie Abbink, Margot Jak, Victor Peperzak, Monique C. Minnema
Publikováno v:
eJHaem, Vol 5, Iss 1, Pp 141-146 (2024)
Abstract Response to daratumumab in patients with relapsed/refractory multiple myeloma is heterogeneous, and a reliable biomarker of response is lacking. We aimed to develop a method that identifies response to daratumumab therapy. Patient‐derived
Externí odkaz:
https://doaj.org/article/95d9a0b5891146baa3b34ed4e6f85dfc
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
The introduction of novel agents dramatically improved response and outcomes of multiple myeloma (MM) and led to a sharp decline in the use of allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Thus, recent guidelines do not recommend an
Externí odkaz:
https://doaj.org/article/f3529d442e224ade89fa39162684ba30
Autor:
Darrell White, Gary J. Schiller, Sumit Madan, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane R. Van Domelen, Ohad S. Bentur, Muhamed Baljevic
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveTo identify the optimal dose of selinexor in combination with pomalidomide and dexamethasone (SPd).MethodsAn analysis of efficacy and safety of 2 once-weekly selinexor regimens (60 mg and 40 mg) with pomalidomide and dexamethasone (SPd-60 an
Externí odkaz:
https://doaj.org/article/faf3645ed4d642638bc528022e510fa6
Autor:
Anna Furlan, Michele Cea, Laura Pavan, Monica Galli, Cristina Clissa, Silvia Mangiacavalli, Anna Maria Cafro, Stefania Girlanda, Francesca Patriarca, Claudia Minotto, Giovanni Bertoldero, Gregorio Barilà, Anna Pascarella, Albana Lico, Rossella Paolini, Nicholas Rabassi, Norbert Pescosta, Marika Porrazzo, Giovanni De Sabbata, Alessandra Pompa, Giulia Bega, Stefania Cavallin, Francesca Guidotti, Magda Marcatti, Maurizio Rupolo, Angelo Belotti, Filippo Gherlinzoni, Renato Zambello
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Introduction Ixazomib, lenalidomide, and dexamethasone (IRd) have been approved for the treatment of relapsed/refractory multiple myeloma (RRMM) based on the results of the TOURMALINE‐MM1. Objectives and Methods We conducted a retrospectiv
Externí odkaz:
https://doaj.org/article/0408a307c22a4cd197324662a7fb060f